左氧氟沙星 concomitant 方案与左氧氟沙星序贯方案治疗叙利亚人群幽门螺杆菌感染的2周疗效:随机对照试验研究方案
本研究为开放标签、前瞻性、单中心、平行、阳性对照、优效性随机临床试验,计划在叙利亚人群中招募最多300例18至65岁幽门螺杆菌阳性患者,随机接受左氧氟沙星序贯方案或左氧氟沙星 concomitant 方案作为经验性一线治疗,主要结局为两组一线根除率,一线失败后采用高剂量双联疗法(质子泵抑制剂联合阿莫西林)作为补救治疗。
要点
- 计划招募最多300例18至65岁幽门螺杆菌阳性患者,随机分为左氧氟沙星序贯方案组和左氧氟沙星 concomitant 方案组。
- 主要结局为两组一线治疗根除率,采用意向性分析和符合方案分析评估。
- 一线治疗失败后,高剂量双联疗法(质子泵抑制剂联合阿莫西林)作为补救治疗,其总体根除率为次要结局之一。
核心结论
- 本随机对照试验将首次在叙利亚人群中提供左氧氟沙星序贯方案疗效的客观准确证据。
- 该试验旨在确立左氧氟沙星序贯方案和左氧氟沙星 concomitant 方案作为叙利亚人群经验性一线治疗的疗效。
研究设计与样本
- 开放标签、前瞻性、单中心、平行、阳性对照、优效性随机临床试验。
- 招募18至65岁幽门螺杆菌阳性男性和女性,计划招募最多300例患者,为所需样本量的两倍。
- 150例个体将被随机分配接受左氧氟沙星序贯治疗方案或左氧氟沙星 concomitant 方案。
- 一线治疗失败后,高剂量双联疗法(质子泵抑制剂联合阿莫西林)作为补救治疗。
- 采用意向性分析和符合方案分析评估一线治疗方案的幽门螺杆菌根除率。
关键数值与推荐
- 主要结局为两组一线根除率。
- 次要结局之一为一线治疗方案失败后高剂量双联疗法的总体根除率。
局限性
- 试验注册于2023年10月3日,首次参与者入组尚未开始。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treating Helicobacter pylori is becoming increasingly difficult with the development of bacterial resistance to many established treatment regimens. As a result, researchers are constantly looking for novel and effective treatments. This trial aims to establish the efficacy of levofloxacin-based sequential treatment regimen and concomitant levofloxacin-based regimen as empirical first-line therapy in the Syrian population. METHOD: This is an open-label, prospective, single-center, parallel, active-controlled, superiority, randomized clinical trial. The recruitment will target Helicobacter pylori-positive males and females between the ages of 18 and 65 to evaluate the efficacy of empirical first-line therapy in the Syrian population. We are planning to recruit up to 300 patients which is twice the required sample size. One hundred fifty individuals will be randomly assigned to undergo either a sequential levofloxacin-based treatment regimen or a concomitant levofloxacin-based regimen. High-dose dual therapy (proton-pump inhibitor and amoxicillin) will be the rescue therapy in the event of first-line failure. The first-line eradication rate in both groups is the primary outcome, and one of the secondary outcomes is the overall eradication rate of high-dose dual therapy in the event of first-line treatment protocol failure. Intention-to-treat analysis and per-protocol analysis will be used to evaluate the eradication rates of Helicobacter pylori for first-line treatment protocols. DISCUSSION: For the first time in the Syrian population, this randomized controlled trial will provide objective and accurate evidence about the efficacy of a sequential levofloxacin-based treatment regimen. TRIAL REGISTRATION: ClinicalTrials.gov NCT06065267 . Registered on October 3, 2023. Prospective registered. Enrollment of the first participant has not started yet.
引用
- Alhalabi M, Almokdad R. Efficacy of a 2-week therapy with levofloxacin concomitant versus a levofloxacin sequential regimen for Helicobacter pylori infection in the Syrian population: a study protocol for randomized controlled trial. Trials. 2024. PMID: 38225650. doi:10.1186/s13063-024-07906-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。